Dart Biosciences is developing a first-in-class, IP-protected platform that uses engineered immune cells as living delivery vehicles for genetic medicines. Unlike conventional gene therapy delivery systems such as viral vectors or lipid nanoparticles, which can face targeting limitations, immune activation, redosing challenges, and cargo constraints, our approach is designed to enable more localised delivery to disease-relevant tissues while reducing systemic exposure. The platform is being developed to support precise, controllable transfer of genetic payloads between cells, addressing a key bottleneck in next-generation genetic medicine. By coupling tissue localisation with conditional payload release, the platform aims to improve spatial precision, minimise off-target exposure, and support repeat administration – key constraints that have limited many prior delivery modalities. By building a modular delivery architecture, Dart Biosciences aims to expand the potential of gene therapy across multiple disease areas beyond the reach of existing delivery modalities, and enable new programmes in therapeutic areas.